For decades, the Alzheimer’s disease (AD) treatment landscape remained largely static, focused on symptom management rather than disease modification. But in recent years, the field has entered a transformational period. With the emergence of new biomarkers, approval of novel anti-amyloid...
Expertise: Neuroscience 40 results
Neuroscience
Dr. Martin Strassnig
Neuroscience
Melissa Snyder, Ph.D.
Neuroscience
Gladys Valdez, Ph.D.
In central nervous system (CNS) clinical trials, the integrity of clinician- and patient-reported outcomes is essential to generating reliable, high-quality data. Given the complexity of neurological disorders and the subjective nature of key endpoints, even small inconsistencies in assessment administration...
Alzheimer’s Disease (AD) is a progressive, irreversible brain disorder that affects memory, thinking, and language skills. Age is the best-known risk factor for AD, with symptoms usually appearing after 60 years of age. According to the Alzheimer's Association and the...
Epilepsy is the fourth most common neurological disorder in the world1, affecting over 68 million people globally, and approximately 2.2 million people in the US2. In pediatric populations, it is estimated that about 470,000 US children under the age of 14...